Skip to main content

Innovative strategies to increase engraftment of engineered hematopoietic stem cells and bypass genotoxic conditioning, toward the next-generation gene therapy

Project description

Towards safer gene therapy procedures

Gene therapy for haematopoietic malignancies or inherited haematopoietic diseases entails the ex vivo genetic manipulation of haematopoietic stem or progenitor cells, which are reinfused back into the patient. The concept is that these cells will attach to the bone marrow and reconstitute a healthy haematopoietic and immune system. The scope of the EU-funded IMPROVING-GT project is to address the toxicities associated with the required bone marrow conditioning and the mobilisation of haematopoietic progenitors, which reduce the cells’ reconstitution potential. Researchers will identify milder myeloablative and mobilisation regimens with an ultimate goal to reduce toxicity and improve patients’ clinical outcome.


Net EU contribution
€ 183 473,28
Via Olgettina 60
20132 Milano

See on map

Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 183 473,28